This is health care's Uber moment. Every knowledge-based profession may one day reach the point when AI outperforms the human experts. In medicine, that day appeared to come in April. A group of primarily Harvard and Stanford researchers announced the results of a study that pitted ChatGPT against hundreds of physicians in a diagnostic obstacle course involving written medical mysteries and information from real-world patients. The bot had won, and the humans weren't entirely happy about it.

Health-wise, recent decades have been dominated by a rise in obesity and associated metabolic disease, significantly affecting the life and health span of Americans. GLP-1s provide the first possibility for a widespread improvement in these issues. Beyond this, it increasingly seems as if they may have wider effects on alcohol and substance abuse and other diseases. Continued understanding of this will reshape how we think about health, food, and beyond. American history is marked by crucibles, from the Industrial Revolution to the atomic age, in which both scientific possibility and human character were subjected to extraordinary pressure.

Traditional Chinese Medicine (TCM), as an effective alternative medicine, has been receiving increasing attention. In recent years, the rapid development of large language models (LLMs) tailored for TCM has highlighted the urgent need for an objective and comprehensive evaluation framework to assess their performance on real-world tasks. However, existing evaluation datasets are limited in scope and primarily text-based, lacking a unified and standardized multimodal question-answering (QA) benchmark. To address this issue, we introduce TCM-Ladder, the first comprehensive multimodal QA dataset specifically designed for evaluating large TCM language models. The dataset covers multiple core disciplines of TCM, including fundamental theory, diagnostics, herbal formulas, internal medicine, surgery, pharmacognosy, and pediatrics.

The outspoken longevity scientist David Sinclair has been predicting that one day, you'll go to the doctor and get a prescription that will make you 10 years younger. Now has learned that he has plans to launch human tests of an oral reprogramming drug as part of a $101 million competition organized by the XPrize Foundation. The foundation is offering cash awards to teams able to "restore" a person to an earlier apparent age, as measured by improvements in immune, cognitive, and muscle function. The grand prize goes to any team able to show a 10-year (or greater) relative improvement after one year of treatment. Reached by phone, Sinclair, a biologist at Harvard Medical School, confirmed that he plans to give an oral drug mixture to volunteers in a bid to seek "evidence for age restoration in humans."

Plus: Anthropic has called for a global slowdown in AI development. The Meta hack shows there's more to AI security than Mythos On Monday, reports emerged that attackers had used Meta's AI customer support agent to steal Instagram accounts. Their approach was simple: they asked the agent to link the accounts to email addresses they controlled, and it complied. Since Anthropic announced that its Mythos model was too good at hacking for a general release, cybersecurity concerns have focused on the risk of superpowered AI systems overwhelming computer infrastructure. But the Instagram hack shows that far simpler exploits can still cause damage. As companies offload more work to AI, these comparatively unsophisticated attacks are becoming harder to ignore.

The future of robot armies is here - and it's not what you think Robots are becoming more a part of our lives every year, and worries about a robot army rising up have long plagued the technology. The robot army that saves the world won't be anything like what you imagine. Nope, they aren't little humanoids who can do synchronised martial arts like the ones who dazzled audiences during New Year's festivities in China . And they won't help you find a can of Coke with embarrassing slowness like the man-shaped beast known as Optimus from Elon Musk's Tesla Inc. Instead, they will be microscopic, and mostly made of algae, bacteria and other single-celled organisms.

For people with aquagenic urticaria, even a quick shower has consequences. More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results. While people can be allergic to water, the condition is very rare. Only 100 to 150 cases have ever been reported. Breakthroughs, discoveries, and DIY tips sent six days a week.

Technology Engineering Woman builds EpiPen cannon, because why not? It's not the most efficient way to deliver the life-saving medicine, but it's definitely the most entertaining. More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results. The bolt-action device can hold up to four pens. Breakthroughs, discoveries, and DIY tips sent six days a week.

Predicting potential outcomes of interventions from observational data is crucial for decision-making in medicine, but the task is challenging due to the fundamental problem of causal inference. Existing methods are largely limited to point estimates of potential outcomes with no uncertain quantification; thus, the full information about the distributions of potential outcomes is typically ignored. In this paper, we propose a novel causal diffusion model called DiffPO, which is carefully designed for reliable inferences in medicine by learning the distribution of potential outcomes. In our DiffPO, we leverage a tailored conditional denoising diffusion model to learn complex distributions, where we address the selection bias through a novel orthogonal diffusion loss. Another strength of our DiffPO method is that it is highly flexible (e.g., it can also be used to estimate different causal quantities such as CATE). Across a wide range of experiments, we show that our method achieves state-of-the-art performance.

Japan Approves the World's First Treatment Made With Reprogrammed Human Cells Researchers in Japan pioneered reprogrammed cells 20 years ago. Now the country has given the first-ever authorizations to manufacture and sell medical products based on the technology. Human iPS cell colony established from fibroblasts. Its actual width is approximately 0.5 mm. On March 6, Japan's Ministry of Health, Labor and Welfare officially granted conditional and time-limited marketing authorization to two regenerative medical products derived from reprogrammed iPS cells, marking exactly 20 years since the creation of mouse iPS cells .